Cambridge, MA – January 9, 2023 – OncoPep, Inc. is proud to be a presenter at this year’s Biotech Showcase January 9-11 in San Francisco. The company will be sending members of its executive team including Chief Operating Officer...
Cambridge, MA – June 14, 2022 – OncoPep, Inc. has named Sanghyuck Nam Chief Financial Officer effective May 11th. In addition to his responsibilities for OncoPep’s financial controls and planning, Nam will be integral to continuing...
Cambridge, MA - June 9, 2022 - OncoPep, Inc. is proud to be a participant at this year’s BIO International Convention 2022 conference June 13-16 in San Diego CA. The company will be sending members of its executive team including CEO...
Cambridge, MA - May 17, 2022 - OncoPep, Inc. has named Dr. Victor Moyo Chief Medical Officer effective May 9th. As CMO, Moyo will provide strategic clinical leadership to ensure delivery of OncoPep’s efforts to develop transformative...
Cambridge, MA - December 09, 2021 – OncoPep, Inc., a developer of transformative immunotherapeutics, announced $11 million in Series D funding. The Series D was led by Tera Science and Kukje Pharma with participation from SX Company and...
Cambridge, MA – November 09, 2021 – OncoPep, Inc. today announced it is expanding its Scientific Advisory Board with the addition of Carl Novina, MD, Ph.D. As the leader and founder of the Dana‐Farber/Harvard Cancer Institute’s...
BOSTON – October 15, 2020 – OncoPep, Inc. today announced a licensing agreement with MANA Therapeutics for use of its EDIFY™ platform for the development of an autologous multi-tumor antigen adoptive T cell therapy for the treatment...
BOSTON – August 8, 2018 – OncoPep, Inc. today announced the initiation of a Phase 1b clinical trial evaluating the safety and tolerability of PVX-410, an investigational multi-peptide cancer vaccine, for patients with smoldering...
BOSTON – February 22, 2017 -- OncoPep, Inc. today announced the initiation of a Phase 1b clinical trial evaluating its investigational vaccine product PVX-410for the treatment of patients with metastatic triple negative breast cancer...
BOSTON – November 28, 2016 -- OncoPep, Inc. announced that a Phase 1b clinical trial is underway to evaluate PVX-410, a multi-peptide therapeutic cancer vaccine, as an adjuvant treatment in patients who have completed all planned therapy...